Form 4: Traws Pharma Director, Luba Greenwood, Acquires Stock Options
SEC Form 4 Filing
Director Luba Greenwood acquired stock options in Traws Pharma, Inc. on September 16, 2024.
Summary
- Luba Greenwood, a director of Traws Pharma, Inc., reported a transaction on September 16, 2024.
- Greenwood acquired 164,000 stock options with an exercise price of $0.34.
- The options vest over three years: 33% on the first anniversary, 33% on the second, and 34% on the third.
- The options expire on September 16, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/16/2024 | Date of the stock option transaction. |
| 09/16/2024 | Date of grant of the stock options. |
| 09/16/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.